Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Dec 30, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how safe and effective a combination of two medications, tocilizumab and atezolizumab, is for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that has not responded to previous treatments. This trial is specifically for patients who have already undergone at least one prior treatment and have been treated with an immune therapy shortly before joining the study. To participate, individuals need to be at least 18 years old and have advanced lung cancer that is either Stage IV or has come back after initial treatment.

If you or someone you know is considering joining this trial, it’s important to note that not everyone is eligible. For example, participants cannot have certain genetic mutations that could be treated with other therapies, nor can they have uncontrolled pain or active autoimmune diseases. If enrolled, participants will receive the combination of tocilizumab and atezolizumab and will be closely monitored by the research team for any side effects and how well the treatment is working. This trial aims to provide valuable information that could help improve future treatments for lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
• • Prior exposure to at least 1 line of therapy
• • Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
• • ECOG PS 0-2
• Exclusion Criteria:
• • Presence of a driver mutation that is susceptible to targeted therapy
• • No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
• • Other active invasive malignancy requiring ongoing therapy
• • Evidence of progressing or untreated brain metastases
• • Evidence or history of leptomeningeal disease
• • Uncontrolled tumor related pain
• • History of an autoimmune disease or IPF